Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 11/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798923 | 0.83 | HTR1B (0.62) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL1545429 | 0.81 | HTR1B (0.60) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL3799623 | 0.81 | HTR1B (0.64) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL14893147 | 0.80 | HTR1B (0.59) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL7876385 | 0.80 | HTR1B (0.58) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL10591827 | 0.80 | HTR1B (0.58) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL11543577 | 0.80 | HTR1B (0.58) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL17286567 | 0.79 | HTR1B (0.66) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL7883052 | 0.78 | HTR1B (0.57) | HTR1BMEN1MAPK1KMT2AMAPT | |
| SCHEMBL4073823 | 0.78 | HTR1B (0.60) | HTR1BMEN1MAPK1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283009-B1 | INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-08-29 | — | — | EP | claimed |
| US-8183254-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2012-05-22 | — | — | US | claimed |
| EP-2283009-A1 | INHIBITORS OF JNK | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | claimed |
| US-20090318484-A1 | Inhibitors of JNK | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | claimed |
| WO-2009138340-A1 | INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-19 | — | — | WO | claimed |
| US-8642601-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642601-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2283009-B1 | INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-8183254-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183254-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183254-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110301170-A1 | Inhibitors of JNK | GONG LEYI (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301170-A1 | Inhibitors of JNK | GONG LEYI (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301171-A1 | Inhibitors of JNK | ARZENO HUMBERTO BARTOLOME (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2283009-A1 | INHIBITORS OF JNK | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20090318484-A1 | Inhibitors of JNK | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318484-A1 | Inhibitors of JNK | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318484-A1 | Inhibitors of JNK | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| WO-2009138340-A1 | INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138340-A1 | INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318484-A1 | Inhibitors of JNK | MAPK1, MAP3K6, MAP3K1 | HTR1B 2147/4885MEN1 3315/4885MAPK1 1/4885 |
| US-20110301170-A1 | Inhibitors of JNK | MAPK6, MAP3K6, MAPK1 | HTR1B 2965/4885MEN1 2781/4885MAPK1 3/4885 |
| US-20110301171-A1 | Inhibitors of JNK | MAPK9, MAP3K9, MAPK1 | HTR1B 2344/4885MEN1 2944/4885MAPK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.